Towards treatments for VEXAS.

VEXAS is a heterogenous disease in its clinical manifestations, with multi-organ involvement and variable marrow dysfunction: responses to therapy will need to be carefully categorized across organ systems. While all included patients treated with azacytidine in this cohort met the criteria for MDS based on WHO 2016, the indication for treatment was uncontrolled inflammation despite chronic corticosteroid therapy in 8/11 cases. VEXAS is a new hematologic disease. [Extracted from the article]